Dr. Haerizadeh joined EXUMA Biotechnology in 2016 where he is responsible for the development of global high throughput molecular screening technologies as well as the engineering of novel cell substrates. Dr. Haerizadeh joined EXUMA Biotech most recently from Synthetic Genomics Inc., where he was responsible for leads and platforms in the mammalian synthetic biology and xenotransplantation division. Previously, he was Director of genome editing and cell engineering division at Intrexon Corporation, where he focused on molecular and cellular engineering tools and platforms for health-related applications. Prior to Intrexon, Dr. Haerizadeh was a group leader in synthetic biology division at Life Technologies Corporation, a global leader in life science research tools, where he led various programs for mammalian synthetic biology and cell engineering related products and services including genome editing technologies. He was also involved in business development evaluation across the synthetic biology division. Prior to Life Technologies, Dr. Haerizadeh held key R&D roles at Codexis Inc., a leading protein engineering and enzyme evolution company. Dr. Haerizadeh received his PhD in molecular and systems biology from the University of Melbourne, Australia. He completed postdoctoral fellowships at Stanford University and the University of Melbourne.
Farzad Haerizadeh, Ph.D.VP Platform Development